PF-06651600 specifically targets the ATP (adenosine triphosphate)-binding domain of JAK3 (Janus kinase 3). Loss of function of JAK3 is associated with severe combined immunodeficiency syndrome.
PF-06651600 is a potent and selective JAK3 inhibitor.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.